Roivant Sciences Bearish Build
Roivant Sciences (ROIV) has experienced a steady climb in short interest, which reached 5.7% of the free float as of November 5, 2026. This marks the highest level of short interest for the company in at least a year. The build-up follows a notable step-change in early October, where short positions increased from approximately 36 million to significantly higher levels. While borrowing costs remain relatively low at 0.42%, the consistent accumulation of short positions indicates growing skepticism among market participants regarding the company's valuation.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.